News 24.10.2017 Neurimmune announced today that it has raised $150 million to fund its growth strategy. The financing will accelerate the development of Neurimmune's human antibody pipeline through clinical proof of concept. Neurimmune receives a one-time $150 million payment from its collaboration partner Biogen in exchange for a 15% reduction in the previously...
News 30.08.2017 Biogen (NASDAQ: BIIB) announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease. The updated analyses include data from the placebo-controlled period and LTE for patients treated with aducanumab up to 24...
News 28.08.2017 Virometix today announced that it has raised CHF 1.2 million from new shareholders in an extension to its recent Series A financing round. The additional funds will be used to further speed up development of its vaccine candidates for RSV and cancer immunotherapy. Furthermore, the company announced the appointment of...
News 14.07.2017 Bio-Technopark based startup Biognosys offering proteomics solutions has raised $5 million from new and existing investors in an extended series C round. The funds will be used to bring proteomics to the broader life science research market. Biognosys is a proteomics company offering innovative services and products for highly multiplexed protein...
News 07.07.2017 Zurich – The greater Zurich region has all the aces needed for a successful biotechnology centre, says Roger Nitsch, president of the Schlieren-based company Neurimmune. It has the best and the brightest – and the right infrastructure in the shape of the Bio-Technopark Schlieren-Zurich. The greater Zurich region is well on...